WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2022)
Top diagnostic & research stocks in 2022 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
LNTH
LANTHEUS HOLDINGS INC
$3.82B$801.46M$216.34M$107.04M$1.55105.61%19.82%N/A13.03%
SHC
SOTERA HEALTH CO
$2.38B$993.35M$404.85M$122.15M$0.439.51%N/A290.91%N/A
SYNH
SYNEOS HEALTH INC
$3.51B$5.41B$711.83M$286.93M$2.798.57%21.99%15.77%N/A
QDEL
QUIDELORTHO CORP
$6.09B$3.04B$1.29B$809.75M$18.9562.29%69.71%-9.68%N/A
FLGT
FULGENT GENETICS INC
$1.06B$802.94M$400.34M$271.57M$8.99-22.49%108.65%-57.33%137.09%
BWAY
BRAINSWAY LTD
$30.62M$29.61M-$9.07M-$10.83M-$0.644.82%N/AN/AN/A
CODX
CO-DIAGNOSTICS INC
$89.66M$53.22M$17.55M$15.17M$0.49-49.14%537.25%-66.89%N/A
NEOG
NEOGEN CORP
$1.67B$531.20M$68.88M$36.44M$0.348.98%7.57%-42.37%-5.45%2022-12-19
TWST
TWIST BIOSCIENCE CORP
$1.46B$203.57M-$191.55M-$217.86M-$4.0453.83%80.02%N/AN/A2023-02-02
DMTK
DERMTECH INC
$69.49M$14.69M-$110.81M-$114.51M-$3.8436.08%N/AN/AN/A
DXCM
DEXCOM INC
$45.13B$2.79B$432.20M$230.00M$0.5920.42%33.09%-61.06%N/A
PHG
KONINKLIJKE PHILIPS NV
$12.36B$19.50B$5.37B$3.77B$4.17-7.66%1.23%160.95%20.18%2023-01-24
A
AGILENT TECHNOLOGIES INC
$44.81B$6.66B$1.91B$1.33B$4.428.42%8.67%36.42%17.54%
MEDP
MEDPACE HOLDINGS INC
$6.34B$1.37B$307.01M$226.73M$6.7925.69%26.06%33.14%57.98%
QGEN
QIAGEN NV
$11.09B$2.23B$864.72M$488.01M$2.14-0.65%9.92%57.35%40.63%2023-02-06
SERA
SERA PROGNOSTICS INC
$38.15M$229.00k-$45.84M-$46.92M-$1.13269.35%N/AN/AN/A
ICLR
ICON PLC
$16.34B$7.66B$1.30B$464.33M$5.8075.96%34.54%45.36%2.05%
TMO
THERMO FISHER SCIENTIFIC INC
$215.92B$44.17B$11.60B$7.03B$17.9413.08%17.38%-17.37%24.82%2023-01-31
DGX
QUEST DIAGNOSTICS INC
$16.97B$10.29B$2.19B$1.24B$10.39-6.81%7.72%-38.77%16.27%2023-02-01
SENS
SENSEONICS HOLDINGS INC
$497.39M$14.83M$234.25M$214.99M$0.499.39%31.71%N/AN/A
DRIO
DARIOHEALTH CORP
$110.66M$26.88M-$66.94M-$73.03M-$3.2162.24%43.41%N/AN/A
LHDX
LUCIRA HEALTH INC
$13.24M$212.13M-$133.85M-$143.28M-$3.51558.80%N/AN/AN/A
CDNA
CAREDX INC
$706.16M$318.63M-$62.13M-$74.44M-$1.4115.52%46.83%N/AN/A
CSTL
CASTLE BIOSCIENCES INC
$627.43M$123.74M-$54.33M-$52.95M-$2.0543.31%N/AN/AN/A
BNGO
BIONANO GENOMICS INC
$641.36M$25.89M-$112.17M-$116.87M-$0.4165.22%N/AN/AN/A
LH
LABORATORY CORP OF AMERICA HOLDINGS
$20.75B$15.26B$3.26B$1.76B$18.88-7.83%9.03%-33.57%22.48%
DHR
DANAHER CORP
$193.16B$31.25B$10.63B$6.64B$9.2011.35%11.88%14.71%21.89%2023-01-25
GENE
GENETIC TECHNOLOGIES LTD
$20.31M$4.79M-$5.03M-$5.02M-$0.345,105.78%63.91%N/AN/A
IDXX
IDEXX LABORATORIES INC
$34.40B$3.34B$983.30M$669.65M$7.966.53%11.87%-10.26%20.45%2023-01-31
MXCT
MAXCYTE INC
$551.05M$41.99M-$21.32M-$23.64M-$0.2330.18%N/AN/AN/A
WAT
WATERS CORP
$20.06B$2.95B$993.31M$696.93M$11.517.81%5.56%2.49%10.97%2023-01-30
NRC
NATIONAL RESEARCH CORP
$968.14M$151.72M$52.42M$34.79M$1.395.05%5.51%-2.11%21.27%2023-02-06
BNR
BURNING ROCK BIOTECH LTD
$250.42M$79.05MN/A-$139.94M-$1.343.43%N/AN/AN/A
CHEK
CHECK-CAP LTD
$21.03M$0.00-$19.43M-$19.30M-$4.40N/AN/AN/AN/A
PRPO
PRECIPIO INC
$16.93M$9.46M-$10.56M-$12.12M-$0.5213.18%35.58%N/AN/A
BIOC
BIOCEPT INC
$12.11M$50.12M-$14.01M-$16.54M-$1.00-23.81%56.35%N/AN/A
MOTS
MOTUS GI HOLDINGS INC
$5.59M$582.00k-$17.60M-$19.73M-$9.9577.44%N/AN/AN/A
STIM
NEURONETICS INC
$164.15M$62.03M-$31.07M-$36.51M-$1.3611.03%N/AN/AN/A
PSNL
PERSONALIS INC
$111.71M$69.01M-$95.13M-$102.45M-$2.27-18.80%N/AN/AN/A
BVS
BIOVENTUS INC
$171.02M$516.70M-$108.32M-$127.14M-$2.0629.47%N/AN/AN/A
ME
23ANDME HOLDING CO
$1.38B$297.62M-$284.35M-$314.54M-$0.7215.13%N/AN/AN/A
IQV
IQVIA HOLDINGS INC
$38.98B$14.31B$2.87B$1.18B$6.265.70%8.63%56.50%N/A
MYGN
MYRIAD GENETICS INC
$1.58B$661.40M-$65.30M-$77.30M-$0.97-3.36%-1.95%N/AN/A
AWH
ASPIRA WOMEN's HEALTH INC
$46.04M$7.88M-$30.74M-$31.03M-$0.2723.02%20.30%N/AN/A
ONVO
ORGANOVO HOLDINGS INC
$13.24M$1.58M-$11.76M-$11.95M-$1.37N/A-18.21%N/AN/A
HSKA
HESKA CORP
$703.88M$259.04M-$4.29M-$16.22M-$1.573.62%14.29%N/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$32.41B$3.90B$1.19B$837.54M$36.927.75%7.98%14.23%17.01%
CNTG
CENTOGENE NV
$19.77M$136.66M-$25.55M-$48.50M-$2.340.09%N/AN/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$10.75B$3.78B$864.40M$436.39M$8.6210.37%15.42%8.84%15.63%
RNLX
RENALYTIX PLC
$82.76M$3.46M-$46.60M-$47.12M-$1.2675.22%N/AN/AN/A
OPGN
OPGEN INC
$7.25M$3.31M-$27.77M-$40.73M-$0.93-21.77%0.52%N/AN/A
OLK
OLINK HOLDING AB (PUBL)
$2.56B$125.65M-$7.65M-$26.25M-$0.21166.41%N/AN/AN/A
VIVO
MERIDIAN BIOSCIENCE INC
$1.39B$333.02M$72.02M$42.46M$0.974.76%10.65%-41.21%13.72%2023-02-02
XGN
EXAGEN INC
$39.33M$45.42M-$35.38M-$40.09M-$2.34-5.93%N/AN/AN/A
ISPC
ISPECIMEN INC
$12.83M$9.99M-$9.93M-$10.14M-$0.84-11.63%N/AN/AN/A
AXDX
ACCELERATE DIAGNOSTICS INC
$75.32M$13.12M-$62.21M-$70.50M-$0.9713.64%44.32%N/AN/A
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA INC
$2.06B$136.97M-$266.64M-$299.19M-$1.3612.61%7.76%N/AN/A
ANIX
ANIXA BIOSCIENCES INC
$153.00M$0.00-$14.09M-$14.13M-$0.47-100.00%-100.00%N/AN/A2022-12-28
PKI
PERKINELMER INC
$17.34B$4.57B$1.40B$631.71M$4.95-3.93%15.91%-51.09%6.40%2023-01-30
NTRA
NATERA INC
$3.79B$776.00M-$508.04M-$545.79M-$5.6937.38%30.85%N/AN/A
NEO
NEOGENOMICS INC
$1.46B$496.76M-$95.80M-$163.32M-$1.332.51%16.95%N/AN/A
HTGM
HTG MOLECULAR DIAGNOSTICS INC
$3.04M$6.80M-$20.08M-$22.09M-$2.45-21.00%-3.93%N/AN/A
MYNZ
MAINZ BIOMED NV
$124.26M$399.84k-$23.76M-$24.03M-$0.02-46.27%N/AN/AN/A
CEMI
CHEMBIO DIAGNOSTICS INC
$9.87M$59.75M-$30.88M-$36.41M-$1.2459.46%21.81%N/AN/A
BMRA
BIOMERICA INC
$51.09M$19.25M-$4.45M-$5.06M-$0.40163.05%27.00%N/AN/A2023-01-11
EXAS
EXACT SCIENCES CORP
$8.21B$2.01B-$483.48M-$716.37M-$4.1113.95%56.46%N/AN/A
SQL
SEQLL INC
$4.86M$113.62k-$3.98M-$4.26M-$0.34-61.17%N/AN/AN/A
OPK
OPKO HEALTH INC
$1.07B$1.22B-$241.53M-$316.95M-$0.45-34.68%4.56%N/AN/A
RDNT
RADNET INC
$1.19B$1.38B$244.37M$7.76M$0.126.94%8.64%-81.82%-12.20%
GH
GUARDANT HEALTH INC
$5.07B$430.76M-$542.29M-$605.57M-$5.9325.27%N/AN/AN/A
PMD
PSYCHEMEDICS CORP
$32.01M$25.97M$678.00k-$2.02M-$0.369.09%-8.59%N/AN/A
NDRA
ENDRA LIFE SCIENCES INC
$10.68M$0.00-$12.77M-$12.99M-$0.26N/A-100.00%N/AN/A
GTH
GENETRON HOLDINGS LTD
$95.50M$76.04MN/A-$97.40M-$1.0611.01%N/AN/AN/A
SLNO
SOLENO THERAPEUTICS INC
$8.08M$0.00-$19.16M-$21.41M-$3.31N/AN/AN/AN/A
NOTV
INOTIV INC
$134.88M$427.27M-$30.04M-$83.48MN/A467.40%78.58%N/AN/A2022-12-12
LAB
STANDARD BIOTOOLS INC
$107.84M$109.19M-$174.48M-$178.68M-$2.30-20.25%1.92%N/AN/A
AKU
AKUMIN INC
$92.35M$744.44M$69.40M-$146.87M-$1.69141.30%N/AN/AN/A
PRE
PRENETICS GLOBAL LTD
$205.31M$441.84MN/A-$358.34M-$14.10N/AN/AN/AN/A
CDIO
CARDIO DIAGNOSTICS HOLDINGS INC
$20.63M$0.00-$1.27M-$1.28M-$0.89N/AN/AN/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$25.28MN/AN/AN/AN/AN/AN/AN/AN/A
CELC
CELCUITY INC
$124.45M$0.00-$33.45M-$35.54M-$2.38N/AN/AN/AN/A
ILMN
ILLUMINA INC
$32.40B$4.70B-$3.68B-$4.15B-$26.439.79%12.63%N/AN/A
SRDX
SURMODICS INC
$502.07M$99.95M-$12.22M-$27.27M-$1.96-4.93%6.45%N/AN/A2023-02-01
QTNT
QUOTIENT LTD
$2.40M$37.63M-$127.31M-$155.53M-$53.211.85%10.25%N/AN/A2023-02-06
VNRX
VOLITIONRX LTD
$120.22M$200.92k-$29.74M-$31.06M-$0.57142.32%N/AN/AN/A
BDSX
BIODESIX INC
$56.41M$35.83M-$46.32M-$58.39M-$1.73-51.79%N/AN/AN/A2022-12-15
ENZ
ENZO BIOCHEM INC
$86.72M$107.07M-$15.59M-$18.26M-$0.38-9.05%0.37%N/AN/A2022-12-13
TTOO
T2 BIOSYSTEMS INC
$11.13M$23.80M-$55.28M-$64.38M-$16.45-17.54%43.48%N/AN/A
TRIB
TRINITY BIOTECH PLC
$26.34M$78.77MN/A-$21.93MN/A-32.22%-4.43%N/AN/A
MDXH
MDXHEALTH SA
$116.51MN/AN/AN/AN/AN/AN/AN/AN/A
NVTA
INVITAE CORP
$619.38M$519.97M-$3.07B-$3.21B-$13.8919.60%58.45%N/AN/A
OABI
OMNIAB INC
$423.16M$51.57MN/A-$43.60MN/AN/AN/AN/AN/A
LMDX
LUMIRADX LTD
$371.39M$331.61M-$101.55M-$336.61M-$1.05-20.18%N/AN/AN/A
VRAX
VIRAX BIOLABS GROUP LTD
$14.79M$0.00-$1.69M-$1.71M-$0.67-100.00%N/AN/AN/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Dec 2022?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Lantheus Holdings (NASDAQ:LNTH)


Lantheus Holdings (NASDAQ:LNTH) is the top diagnostic & research stock with a Zen Score of 59, which is 28 points higher than the diagnostic & research industry average of 31. It passed 19 out of 33 due diligence checks and has strong fundamentals. Lantheus Holdings has seen its stock return 108.34% over the past year, overperforming other diagnostic & research stocks by 133 percentage points.

Lantheus Holdings has an average 1 year price target of $107.25, an upside of 93.31% from Lantheus Holdings's current stock price of $55.48.

Lantheus Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Lantheus Holdings, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the second best diagnostic & research stock with a Zen Score of 58, which is 27 points higher than the diagnostic & research industry average of 31. It passed 19 out of 33 due diligence checks and has strong fundamentals. Sotera Health Co has seen its stock lose -61.03% over the past year, underperforming other diagnostic & research stocks by -37 percentage points.

Sotera Health Co has an average 1 year price target of $13.56, an upside of 60.62% from Sotera Health Co's current stock price of $8.44.

Sotera Health Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Sotera Health Co, 0% have issued a Strong Buy rating, 20% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 30% have issued a Strong Sell.

3. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the third best diagnostic & research stock with a Zen Score of 56, which is 25 points higher than the diagnostic & research industry average of 31. It passed 18 out of 33 due diligence checks and has strong fundamentals. Syneos Health has seen its stock lose -65.5% over the past year, underperforming other diagnostic & research stocks by -41 percentage points.

Syneos Health has an average 1 year price target of $52.29, an upside of 53.15% from Syneos Health's current stock price of $34.14.

Syneos Health stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Syneos Health, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 55.56% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 9 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Koninklijke Philips Nv (NYSE:PHG)


Koninklijke Philips Nv (NYSE:PHG) has an annual dividend yield of 6.79%, which is 5 percentage points higher than the diagnostic & research industry average of 1.95%. Koninklijke Philips Nv's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Koninklijke Philips Nv's dividend has not shown consistent growth over the last 10 years.

Koninklijke Philips Nv's dividend payout ratio of 24.8% indicates that its high dividend yield is sustainable for the long-term.

2. Psychemedics (NASDAQ:PMD)


Psychemedics (NASDAQ:PMD) has an annual dividend yield of 4.59%, which is 3 percentage points higher than the diagnostic & research industry average of 1.95%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -52.8% indicates that its high dividend yield might not be sustainable for the long-term.

3. National Research (NASDAQ:NRC)


National Research (NASDAQ:NRC) has an annual dividend yield of 2.14%, which is the same as the diagnostic & research industry average of 1.95%. National Research's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. National Research's dividend has shown consistent growth over the last 10 years.

National Research's dividend payout ratio of 60.4% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1% in the last day, and up 0.92% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Sotera Health Co has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Sotera Health Co's stock has dropped -61.03% in the past year. It has underperformed other stocks in the diagnostic & research industry by -37 percentage points.

2. Quidelortho (NASDAQ:QDEL)


Quidelortho (NASDAQ:QDEL) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Quidelortho has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Quidelortho's stock has dropped -34.01% in the past year. It has underperformed other stocks in the diagnostic & research industry by -10 percentage points.

3. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Syneos Health has a valuation score of 86, which is 53 points higher than the diagnostic & research industry average of 33. It passed 6 out of 7 valuation due diligence checks.

Syneos Health's stock has dropped -65.5% in the past year. It has underperformed other stocks in the diagnostic & research industry by -41 percentage points.

Are diagnostic & research stocks a good buy now?

45.88% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 22.47% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 35.8x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.